Minerva Neurosciences | NERV - Assets


Minerva Neurosciences reported $97.97M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Adma Biologics USD 684.21M 19.03M Jun/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
AstraZeneca USD 115.83B 1.82B Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Cipla INR 424.96B 23.32B Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 145.86M 10.71M Mar/2026
CSL USD 37.9B 1.5B Dec/2025
Eli Lilly USD 142.28B 25.71B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
J&J USD 201.06B 167M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Novavax USD 955.58M 87.59M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Takeda JPY 15.66T 210.16B Jun/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025